Paragangliomas Approved for Marketing Phase Trials for Iobenguane (DB06704)

Back to Paragangliomas

Also known as: Paraganglioma / Paraganglion neoplasm / Paraganglion neoplasm NOS / Neoplasm of paraganglion (disorder) / [M]Paraganglioma NOS (morphologic abnormality) / Gangliocytic paraganglioma (disorder) / Gangliocytic paraganglioma (morphologic abnormality) / Paraganglioma (morphologic abnormality) / Paraganglioma (disorder)

Indication	Status	Phase
DBCOND0051744 (Paragangliomas)	Approved for Marketing	Not Available

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01377532	Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma		Iobenguane (DB06704)
NCT02961491	Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma		Iobenguane (DB06704)